Skip to content

Study · Measured the body's own peptide · 2013

7 results

Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis.

Mily A, Rekha RS, Kamal SM, Akhtar E, Sarker P, Rahim Z, Gudmundsson GH, Agerberth B, Raqib R

BMC pulmonary medicine16 Apr 2013Cited by 77 (Europe PMC)

Summary

BackgroundWe earlier showed that 4-phenylbutyrate (PB) can induce cathelicidin LL-37 expression synergistically with 1,25-dihydroxyvitamin D3 in a lung epithelial cell line. We aimed to evaluate a therapeutic dose of PB alone or in combination with vitamin D3 for induction of LL-37 expression in immune cells and enhancement of antimycobacterial activity in monocyte-derived macrophages (MDM).MethodsHealthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days. Blood was collected on day-0, day-4 and day-8; plasma was separated, peripheral blood mononuclear cells (PBMC), non-adherent lymphocytes (NAL) and MDM were cultured. LL-37 transcript in cells and peptide concentrations in supernatant were determined by qPCR and ELISA, respectively. In plasma, 25-hydorxyvitamin D3 levels were determined by ELISA. MDM-mediated killing of Mycobacterium tuberculosis (Mtb) (H37Rv) was performed by conventional culture method.ResultsMDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05). Both Group-I and -II exhibited higher levels of transcript on day-4 compared to Group-III and Group-V (p < 0.035). Increased induction of peptide was observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p < 0.05), while Group-IV showed increased levels on day-8 compared to Group-I and Group-III (p < 0.04). Intracellular killing of Mtb on day-4 was significantly increased compared to day-0 in Group-I, -II and -V (p < 0.05).ConclusionThe results demonstrate that 500 mg b.d. PB with 5000 IU o.d. vitamin D3 is the optimal dose for the induction of LL-37 in macrophages and lymphocytes and intracellular killing of Mtb by macrophages. Hence, this dose has potential application in the treatment of TB and is now being used in a clinical trial of adults with active pulmonary TB (NCT01580007).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialEfficacy outcome

    In healthy volunteers, oral phenylbutyrate 500 mg twice daily with vitamin D3 increased LL‑37 peptide concentration in monocyte-derived macrophages at day 4 versus day 0.

    In plain wordsIn healthy volunteers, phenylbutyrate with vitamin D raised the body's own LL‑37 in macrophages after four days, compared with day 0.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 peptide in macrophages, Group-II, day 4
    Study

    n: not reported in source

    Comparator
    Day-0
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05).
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelNon-randomized trialEfficacy outcome

    In healthy volunteers, oral phenylbutyrate 500 mg twice daily with vitamin D3 increased LL‑37 transcript in monocyte-derived macrophages at day 4 versus day 0.

    In plain wordsIn healthy volunteers, phenylbutyrate with vitamin D raised the body's own LL‑37 gene activity in macrophages after four days, compared with day 0.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 transcript in macrophages, Group-II, day 4
    Study

    n: not reported in source

    Comparator
    Day-0
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05).
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelNon-randomized trialEfficacy outcome

    In healthy volunteers, oral phenylbutyrate 250 mg twice daily with vitamin D3 increased LL‑37 transcript in monocyte-derived macrophages at day 4 and day 8 versus day 0.

    In plain wordsIn healthy volunteers, a lower phenylbutyrate dose with vitamin D raised the body's own LL‑37 gene activity in macrophages on days four and eight.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 transcript in macrophages, Group-I, days 4 and 8
    Study

    n: not reported in source

    Comparator
    Day-0
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05).
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelNon-randomized trialEfficacy outcome

    At day 4, LL‑37 transcript levels in macrophages were higher in the groups given phenylbutyrate 250 mg or 500 mg twice daily with vitamin D3 than in the 1000 mg group and the vitamin D3-only group.

    In plain wordsNatural LL‑37 in macrophages was higher at day four with two lower doses plus vitamin D than with the top dose or vitamin D alone.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 transcript in macrophages, Groups I and II versus Groups III and V, day 4
    Study

    n: not reported in source

    Comparator
    Group-III and Group-V
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Both Group-I and -II exhibited higher levels of transcript on day-4 compared to Group-III and Group-V (p < 0.035).
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelNon-randomized trialEfficacy outcome

    At day 4, LL‑37 peptide induction in non-adherent lymphocytes was higher with phenylbutyrate 500 mg twice daily plus vitamin D3 than with the 250 mg plus vitamin D3 group and the phenylbutyrate-only group.

    In plain wordsNatural LL‑37 in lymphocytes was higher at day four with the middle dose plus vitamin D than with the low dose or phenylbutyrate alone.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 peptide in lymphocytes, Group-II versus Groups I and IV, day 4
    Study

    n: not reported in source

    Comparator
    Group-I and Group-IV
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Increased induction of peptide was observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p < 0.05)
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelNon-randomized trialEfficacy outcome

    At day 8, LL‑37 peptide induction in non-adherent lymphocytes was higher with phenylbutyrate 500 mg twice daily alone than with the 250 mg and 1000 mg groups given vitamin D3.

    In plain wordsOn day eight, the body's own LL‑37 in lymphocytes was higher with phenylbutyrate alone than with the lowest or highest dose given with vitamin D.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 peptide in lymphocytes, Group-IV versus Groups I and III, day 8
    Study

    n: not reported in source

    Comparator
    Group-I and Group-III
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    while Group-IV showed increased levels on day-8 compared to Group-I and Group-III (p < 0.04).
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone1

In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LL-37.

  1. 07HumanNot a test of LL-37 aloneNon-randomized trialEfficacy outcome

    In healthy volunteers, intracellular killing of Mycobacterium tuberculosis by macrophages was significantly increased at day 4 versus day 0 in Groups I and II (phenylbutyrate with vitamin D3) and in Group V (vitamin D3 alone).

    In plain wordsIn healthy volunteers, macrophages killed more tuberculosis bacteria at day four than at day 0 after phenylbutyrate with vitamin D or vitamin D alone.

    Peptide
    LL-37
    Outcome
    IncreaseIntracellular killing of M. tuberculosis by macrophages, day 4
    Study

    n: not reported in source

    Comparator
    Day-0
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Intracellular killing of Mtb on day-4 was significantly increased compared to day-0 in Group-I, -II and -V (p < 0.05).
    1 context sentence
    Summary · context
    Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.